Skip to main content
. 2017 Apr 4;127(5):1757–1771. doi: 10.1172/JCI87388

Figure 5. ω-3 PUFAs exert a therapeutic effect on hyperglycemia in diabetic NOD mice.

Figure 5

(A) Nonfasting blood glucose levels in diabetic NOD mice (nonfasting blood glucose levels for 2 consecutive weeks = 11.1–20 mmol/l) after i.v. tail-vein injection of lenti-con (black, n = 7) or lenti-mfat-1 (green, n = 7), or DHA plus EPA dietary intervention (purple, n = 7). ***P < 0.0001 versus the lenti-con group (Student t test). (B and C) Concentrations of nonfasting serum insulin and BHOB, the ketone metabolite, in nondiabetic and diabetic NOD mice (nonfasting blood glucose levels <20 mmol/l for 2 consecutive weeks) before treatment; diabetic NOD mice (nonfasting blood glucose level for 2 consecutive weeks = 11.1–20 mmol/l) after lentivirus injection; or in mice that received DHA plus EPA diet intervention for 9 weeks. *P < 0.05, **P < 0.01, and ***P < 0.0001 versus the nondiabetic group (n = 5–10/group) (Student’s t test). Each point represents an individual mouse, and data are representative of 2 independent experiments. All values represent the mean ± SEM.